Methotrexate

Monopgraph
Therapeutic action
- MTX is an antimetabolite structural analog of folic acid. It is used in many antineoplastic therapies and as an immunosuppressant.Cancer chemotherapy:
- Lymphocytic leukemia and acute lymphocytic, with or without meningeal involvement
- L
- Lymphosarcoma, especially in children and Burkitt
- Breast cancer
- Ovarian cancer
- Bladder cancer
- Choriocarcinoma
- Osteosarcoma
- Tumors of head and neck squamous
- Small cell lung carcinomaImmunosuppressant:
- Crohn’s Disease
- Graft versus host disease
- Psoriasis
- Psoriatic arthritis
- Rheumatoid arthritis
More information
Methylenetetrahydrofolate reductase (MTHFR) catalyses the irreversible conversion of 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate in the folic acid cycle.
The C677T (rs1801133) and A1298C (rs1801131) polymorphisms have been described as modifiers of the therapeutic effects of methotrexate.
The C677T polymorphism causes an amino acid substitution from alanine to valine in the catalytic domain, resulting in a thermolabile protein. In White populations, approximately 10% of individuals are homozygous for the variant and 40% are heterozygous, with approximately 30% and 60% of normal enzymatic activity, respectively (Molloy et al., 1997).
In patients treated with methotrexate, this variation has been associated with hepatotoxicity and mucositis (Ulrich et al., 2001).
The A1298C polymorphism also causes an amino acid substitution, from glutamic acid to alanine, producing a protein with reduced enzymatic activity. However, this polymorphism alone does not appear to have a significant effect. Increased homocysteine concentrations have mainly been observed when it is present in combination with C677T.
Metabolism
Methotrexate and its polyglutamated derivatives inhibit purine and pyrimidine synthesis by inhibiting enzymes involved in these pathways: dihydrofolate reductase (DHFR), thymidylate synthase (TS) and, indirectly, methylenetetrahydrofolate reductase (MTHFR).
DHFR is responsible for converting folic acid into tetrahydrofolate (THF), a cofactor required for the transfer of one-carbon units during the synthesis of purines and pyrimidines, which are precursors of DNA and RNA. Inhibition of TS also results in inhibition of DNA synthesis.
Methotrexate enters cells through two transport mechanisms: i) the reduced folate carrier (RFC1), which has a high affinity for both methotrexate and reduced folates; and ii) passive diffusion.
Once inside the cell, the glutamic acid side chain of methotrexate is polymerised to form methotrexate polyglutamates. Both methotrexate and its polyglutamated derivatives inhibit DHFR.
Conclusions
Individualising methotrexate treatment according to the MTHFR C677T and A1298C polymorphisms may be important for reducing the risk of toxicity.
A classification based on combinations of these polymorphisms has been proposed, distinguishing genotypes associated with reduced enzymatic activity, such as variant homozygotes or compound heterozygotes, from those associated with normal activity, such as wild-type homozygotes or single heterozygotes (Marcuello et al., 2006).
Bibliography
- Molloy AM, et al. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet. 1997 May 31; 349(9065):1591-3.
- Ulrich CM, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood. 2001 Jul 1; 98(1):231-4.
- Marcuello E, et al. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy. Cancer Chemother Pharmacol. 2006 Jun; 57(6):835-4
Additional information
David Páez López-Bravo Licenciado en Medicina Especialidad en Oncología Médica